ATLANT 3D Nanosystems Developing a Space-certified Nanofabricator 0G
31.3.2022 10:59:00 EEST | Business Wire | Press release
ATLANT 3D Nanosystems announces today the collaboration with ESA BIC to further advance the development of ATLANT 3D Nanofabricator™ 0G systems, the first-ever zero gravity R&D system that allows selective area direct write atomic layer precision.
ATLANT 3D™ will develop a space-certified Nanofabricator 0G with the goal of going to the International Space Station (ISS) in future missions. The machine will have the full capabilities of the Nanofabricator Lite system, allowing further testing and development of on-demand electronic materials and micro and nanodevice prototyping. This will further enable researchers and innovators with rapid materials and device development in Space.
This unique technology will be it first of its kind in Space and it all started with NASA purchasing ATLANT 3D’s first 0G system, allowing ATLANT 3D to develop unique new technologies for bringing Microreactor Selective Area Direct Atomic Processing (μSADALP™) technology into Space.
About ATLANT 3D Nanosystems
https://atlant3d.com
ATLANT 3D is a Danish startup company that is developing a fundamentally different and innovative micro and nanofabrication platform technology. ATLANT 3D is a developer of high-performance technology enables atomical precise advanced manufacturing of the next generation of advanced materials and electronics. ATLANT 3D team is highly dynamic, international, and multidisciplinary, consisting of 15 experienced entrepreneurs, engineers and scientists. ATLANT 3D collaborates with leading European universities, such as SAS, DTU, FAU, TNO, SUPSI and industrial partners such as Merck, ST Microelectronics, Prima Industrie and SEMPA.
About ESA BIC
https://www.esabic.dk
ESA BIC Denmark is the 21st member of ESA’s pan-European network of Business Incubation Centres. The incubator is led by The Technical University of Denmark (DTU) in collaboration with the Danish Ministry for Higher Education and Science, University of Aalborg, University of Aarhus, The Danish Industry Foundation and other partners from academia, science parks, industry and Danish government agencies. The main objective of the Danish ESA BIC is to create and strengthen communities of successful space related start-ups in Denmark The activities will contribute significantly to growing clusters of space-based companies in Denmark.
Social media links:
LinkedIn: https://www.linkedin.com/company/atlant3dnano
Twitter: https://twitter.com/Atlant3d
Youtube: https://www.youtube.com/channel/UC6ffxaIzDjy_jr4jILQQaqw
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005773/en/
Contact information
Albina Nazari
Marketing & Communication Manager
ATLANT 3D Nanosystems
Email: an@atlant3d.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom